![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
X
20
Arevipharma Gmbh Radebeul De, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Carvedilol, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2005-155 - Rev 03
This Chemical Type CEP, issued on November 03, 2022, remains in force until July 19, 2023, ensuring its reliability within the pharmaceutical industry.
Substance Number 1745 associated with this CEP further emphasizes